Praluent Standard Titration Schedule: How to Dose Alirocumab Step by Step

What Is the Standard Praluent Titration Protocol?

The FDA-approved titration for alirocumab is a two-step dose ladder: 75 mg every two weeks, then 150 mg every two weeks if needed. Most prescribers reassess LDL-C at four weeks, though the full lipid-lowering effect peaks at about eight weeks after a dose change. This approach limits unnecessary exposure to a higher dose for women who respond well at the lower level.

The FDA prescribing information for alirocumab states that if LDL-C response is inadequate at 75 mg every two weeks, the dose may be increased to 150 mg every two weeks. For patients with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need larger LDL-C reductions, some clinicians start directly at 150 mg every two weeks based on individual cardiovascular risk.

Why a Titration Step Matters for Women

Women's lipid trajectories shift substantially across the reproductive life span. Estrogen raises HDL and suppresses LDL during the reproductive years, so the same cardiovascular risk represented by an LDL-C of 130 mg/dL looks very different at age 32 than at age 58. Perimenopause and the years immediately after the final menstrual period are associated with a rapid rise in LDL-C, small dense LDL particles, and lipoprotein(a), changes that may not be captured in risk calculators calibrated on older male-dominated trial populations.

Because the titration step allows dose adjustment, your prescriber can set a more ambitious LDL-C target if you are post-menopausal with additional risk factors, without automatically exposing every woman to the higher dose.

Who Starts at 150 mg Without Titration?

Some women skip the 75 mg step entirely. The FDA label permits starting at 150 mg every two weeks when a very large LDL-C reduction is needed at the outset. This typically applies to:

• Women with HeFH and a baseline LDL-C above 190 mg/dL on maximally tolerated statin therapy
• Women with established ASCVD (prior MI, stroke, peripheral arterial disease) and an LDL-C still above 70 mg/dL despite statins and ezetimibe
• Post-menopausal women with multiple risk factors whose cardiologist has set a target of <55 mg/dL per recent ACC/AHA guidance

The 2018 ACC/AHA Cholesterol Guideline recommends considering a PCSK9 inhibitor in very high-risk patients when statin plus ezetimibe fails to achieve adequate LDL-C reduction, without mandating a lower starting dose.

Step-by-Step Titration: What Happens at Each Point

Week 0: Starting Injection

You inject 75 mg subcutaneously into the thigh, abdomen, or outer upper arm. The pre-filled pen or syringe should sit at room temperature for 30 to 40 minutes before injection; cold solution increases injection-site discomfort, which matters because injection-site reactions are the most commonly reported adverse event in women.

The FDA label requires you to rotate injection sites with each dose. If you use the abdomen, avoid the two-inch zone around the navel.

Weeks 4 to 8: First Lab Check

A fasting lipid panel at week four tells you whether 75 mg is working. Because alirocumab reaches pharmacokinetic steady state at roughly four weeks, this is the earliest clinically meaningful check. The target reduction is at least 50 percent from baseline LDL-C for most ASCVD patients.

If your LDL-C has not reached your individualized goal, your provider escalates to 150 mg at the next scheduled injection. You do not need to wait until that dose to book your next appointment; the injection schedule every 14 days stays the same.

Week 8 Onward: Confirm Response at 150 mg

After four weeks at 150 mg (so roughly week eight from starting the drug, or week four from the dose change), another fasting lipid panel confirms whether the higher dose is effective. ODYSSEY LONG TERM data showed that 150 mg every two weeks produced a mean LDL-C reduction of approximately 62 percent from baseline, with the response stable through 78 weeks.

If LDL-C reduction is still below goal at 150 mg, the prescriber typically reviews adherence, checks for drug interactions, considers secondary causes of hyperlipidemia (hypothyroidism is common in women and elevates LDL), and may add or optimize ezetimibe rather than exceeding the maximum labeled dose.

How Women's Hormonal Status Changes Your LDL Target

Reproductive Years (Ages 18-40)

LDL-C is generally lower in women of reproductive age compared with age-matched men, partly because estradiol suppresses hepatic LDL receptor downregulation. Women in this group who require alirocumab usually have HeFH, premature ASCVD, or statin intolerance. The titration schedule is the same, but the LDL-C target may differ based on the indication.

Perimenopause (Typically Ages 45-55)

The menopause transition is associated with a clinically meaningful rise in LDL-C, often 10 to 20 mg/dL in the two years around the final menstrual period, according to data from the SWAN study. SWAN cardiovascular data documented that total cholesterol rose by an average of 6.5 percent during the menopausal transition, independent of age and BMI. If you are starting alirocumab during perimenopause, your LDL-C baseline may be a moving target, and reassessment after each dose step is especially important.

Post-Menopause (After Final Menstrual Period)

Post-menopausal women carry a substantially higher absolute cardiovascular risk than pre-menopausal women of the same age. The 2023 Menopause Society position statement on cardiovascular disease notes that women's cardiovascular mortality risk converges with men's within 10 years after menopause. The Menopause Society 2023 cardiovascular statement supports aggressive LDL-C lowering in post-menopausal women with established ASCVD, which often means targeting 150 mg every two weeks from the outset or escalating promptly after the week-four check.

Statin and Hormone Therapy Interactions

Women on menopausal hormone therapy (MHT) using oral estrogen may see modest changes in LDL-C independent of PCSK9 inhibition. Oral estradiol lowers LDL-C, which means your week-four response assessment should account for any recent MHT change. Transdermal estrogen has minimal effect on hepatic lipid metabolism and is less likely to confound your alirocumab response.

The Evidence Behind the Titration Design

The titration schedule was built into the ODYSSEY trial program from its inception. The largest outcomes trial, ODYSSEY OUTCOMES (NEJM 2018), enrolled 18,924 patients with recent acute coronary syndrome and randomized them to alirocumab 75 mg every two weeks versus placebo. Critically, the trial used a blinded titration: patients whose LDL-C remained above 50 mg/dL at eight weeks were escalated to 150 mg every two weeks, and those who dropped below 25 mg/dL were de-escalated back to 75 mg or to placebo.

The result was a 15 percent relative risk reduction in the composite of coronary heart disease death, non-fatal MI, fatal or non-fatal ischemic stroke, or unstable angina requiring hospitalization (hazard ratio 0.85, 95% CI 0.78 to 0.93). The absolute risk reduction was 1.6 percentage points over a median follow-up of 2.8 years, translating to a number needed to treat of 63.

The ODYSSEY OUTCOMES titration algorithm is the direct ancestor of the current FDA label instructions. About 81 percent of patients started and remained at 75 mg, meaning most people never needed the higher dose, a finding that supports the conservative two-step approach.

The WomanRx Titration Decision Tree (adapted from the ODYSSEY OUTCOMES protocol for clinical practice):

1. Confirm baseline fasting LDL-C and rule out secondary causes (thyroid disease, nephrotic syndrome, obstructive liver disease).
2. Inject alirocumab 75 mg subcutaneously on day 1.
3. Recheck fasting LDL-C at week 4 (or week 8 at the latest).
4. If LDL-C is at or below individualized target: continue 75 mg every two weeks.
5. If LDL-C is above target: escalate to 150 mg every two weeks starting at the next injection.
6. Recheck fasting LDL-C four weeks after escalation.
7. If LDL-C is below 25 mg/dL at any point: discuss de-escalation back to 75 mg; very low LDL-C is not proven harmful but long-term data are reassuring only to about 15 mg/dL.

Sex-Specific Pharmacokinetics: Does Your Body Handle Alirocumab Differently?

Yes. Alirocumab is a monoclonal antibody, and like most large biologics, its pharmacokinetics are influenced by body weight and lean body mass. Women have, on average, lower body weight and different fat-to-lean ratios than men.

A population PK analysis from the ODYSSEY program found that lower body weight was associated with higher alirocumab exposure at the same dose, meaning smaller women may achieve a greater LDL-C reduction per milligram than larger men. This has two practical implications:

• Women at the lower end of the weight spectrum may reach their LDL-C goal at 75 mg more often than the average trial participant.
• Conversely, if you are a larger woman with higher volume of distribution, you may need to escalate to 150 mg to achieve the same trough concentration.

The FDA label population PK section confirms that body weight is a statistically significant covariate for alirocumab clearance, though the prescribing information does not recommend weight-based dosing adjustments because the fixed-dose titration handles this empirically.

Sex as a biological variable was not reported as a primary covariate in most ODYSSEY PK substudies, which is a genuine evidence gap. The clinical implication is that the week-four LDL-C check is your empirical calibration, not a one-size-fits-all test.

Female-Relevant Conditions That Affect Alirocumab Prescribing

Familial Hypercholesterolemia

HeFH affects approximately 1 in 250 people, and women with HeFH face a lifetime of elevated LDL-C that statins alone rarely normalize. ODYSSEY FH I and FH II demonstrated that alirocumab 150 mg every two weeks reduced LDL-C by 48 to 49 percent compared with placebo on top of maximally tolerated statin therapy. Women of childbearing age with HeFH face a particular challenge because statins are teratogenic and must be stopped in pregnancy, so alirocumab titration plans need to build in contraceptive counseling from the start.

PCOS and Insulin Resistance

Women with polycystic ovary syndrome have a higher prevalence of dyslipidemia, including elevated LDL-C and elevated non-HDL-C, partly driven by insulin resistance and androgenic lipid effects. No randomized trial has specifically studied alirocumab in women with PCOS. The standard titration schedule applies, but the lipid phenotype in PCOS often includes small dense LDL particles that may not be fully captured by a standard LDL-C measurement. Apolipoprotein B (ApoB) or non-HDL-C may be more informative targets for this group.

Hypothyroidism

Thyroid disease is five to eight times more common in women than men. Untreated or undertreated hypothyroidism elevates LDL-C through reduced LDL receptor expression, and this secondary hyperlipidemia will blunt your response to alirocumab. Before escalating from 75 mg to 150 mg, your provider should confirm that your TSH is within target range.

Post-Menopausal Dyslipidemia

As noted above, the lipid shift after menopause is substantial. Lipoprotein(a), a genetically determined LDL-like particle that carries independent cardiovascular risk, also rises modestly after menopause. Alirocumab reduces Lp(a) by approximately 20 to 30 percent, a clinically relevant secondary benefit in post-menopausal women with elevated Lp(a).

Pregnancy, Lactation, and Contraception: What You Need to Know

Alirocumab is not recommended during pregnancy. The FDA label carries no formal pregnancy category under the current labeling system, but the available animal data and mechanistic concerns about PCSK9 inhibition during fetal development mean most prescribers treat it as contraindicated in pregnancy.

Animal Data

Animal reproduction studies with alirocumab showed no evidence of teratogenicity at exposures substantially higher than the human therapeutic dose. However, animal models do not fully predict human fetal risk with monoclonal antibodies, particularly in the second and third trimesters when maternal IgG crosses the placenta in significant quantities. The FDA label states there are no adequate and well-controlled studies in pregnant women.

Human Data Gap

As of the time of writing, published human pregnancy outcome data for alirocumab are limited to case reports and small registry entries. This is a real and important evidence gap. Women who become pregnant while on alirocumab should contact their prescriber immediately. The drug should be discontinued, and a maternal-fetal medicine specialist should be consulted if exposure occurred in the first trimester.

Lactation

It is not known whether alirocumab is excreted in human breast milk. Monoclonal antibodies are generally large proteins that transfer poorly into milk and have low oral bioavailability in the infant, which provides some theoretical reassurance. However, because human lactation data are absent and cholesterol is important for infant brain development, the FDA label recommends weighing the developmental and health benefits of breastfeeding against the mother's need for alirocumab. Most clinicians advise pausing treatment during lactation and reassessing once breastfeeding is complete.

Contraception Requirements

Women with HeFH or ASCVD who require alirocumab long-term and who are of reproductive potential should discuss reliable contraception with their prescriber. This is especially relevant because many of these women are also on statins (which are clearly teratogenic and require contraception), and the combination requires a coordinated reproductive plan. ACOG Practice Bulletin No. 206 on lipid management addresses statin teratogenicity and contraceptive counseling in women with hyperlipidemia.

If you are planning a pregnancy and currently taking alirocumab, the standard recommendation is to stop the drug before attempting conception. Because alirocumab has a half-life of approximately 17 to 20 days, most prescribers advise stopping it at least four to six weeks before a planned conception attempt to allow washout.

Who This Protocol Is Right For, and Who Should Wait

Right for You If:

• You have established ASCVD (prior MI, stroke, coronary artery disease) and your LDL-C remains above 70 mg/dL despite statin plus ezetimibe.
• You have HeFH with LDL-C above 100 mg/dL on maximally tolerated statin therapy.
• You are post-menopausal with multiple cardiovascular risk factors and a high estimated 10-year ASCVD risk.
• You cannot tolerate statins (confirmed statin-associated muscle symptoms on two separate statins at the lowest dose).

You Should Wait or Reconsider If:

• You are pregnant or planning pregnancy in the next two to three months.
• You are currently breastfeeding.
• Your LDL-C has not been rechecked after optimizing statin dose; alirocumab is an add-on, not a first-line therapy for most women.
• Your LDL-C elevation is secondary to untreated hypothyroidism, nephrotic syndrome, or a new medication.

The Shared Decision Conversation

Two direct quotations frame the clinical standard here. The 2022 ACC Expert Consensus Decision Pathway states: "PCSK9 inhibitors are recommended for patients with ASCVD who are on maximally tolerated statin therapy and whose LDL-C remains above threshold, with dose titration guided by the four-week LDL-C response." The 2018 ODYSSEY OUTCOMES trial investigators noted: "The flexible dosing regimen allowed for a reduction in dose in patients with very low LDL-C values, supporting the safety of the titration approach."

Injection Technique and Titration Timing: Practical Details

Getting the injection right affects both efficacy and tolerability. These steps apply whether you are on 75 mg or 150 mg:

• Remove the pen from the refrigerator 30 to 40 minutes before injecting. Room-temperature injection reduces local stinging.
• Choose a clean, dry area. Avoid skin that is bruised, tattooed, scarred, or actively inflamed.
• Pinch the skin before inserting the needle if you are injecting into the abdomen or thigh.
• Hold the pen firmly against the skin until the injection is complete (about 10 seconds for most auto-injector pens).
• Do not massage the site after injection; this can accelerate absorption unpredictably.
• Mark your calendar. Injections every 14 days means the same day of the week every two weeks.

If you miss a dose, inject as soon as you remember, provided the next scheduled injection is at least seven days away. If the missed dose is within seven days of your next scheduled dose, skip the missed one and resume your regular schedule. Missing a dose does not require restarting the titration.

Monitoring Schedule During Titration

| Timepoint | Action | |---|---| | Baseline | Fasting lipid panel, TSH, liver function tests, CK if symptoms | | Week 4 | Fasting LDL-C; decide 75 mg vs escalate | | Week 8 (or 4 weeks after escalation) | Fasting LDL-C; confirm response at 150 mg | | Every 6-12 months thereafter | Full fasting lipid panel; ApoB or Lp(a) if indicated | | Any new symptoms (muscle pain, cognitive changes) | Contact provider; off-schedule lipid panel |

Injection-site reactions occur in approximately 7 percent of alirocumab-treated patients in clinical trials, compared with 5 percent in placebo groups. These are usually mild and self-limited. Nasopharyngitis and upper respiratory symptoms appear in a similar proportion. Neurocognitive adverse events were studied specifically in the EBBINGHAUS trial, a prospective cognitive assessment nested within ODYSSEY OUTCOMES, which found no difference between alirocumab and placebo on neurocognitive outcomes at a median follow-up of 19 months.